Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer

Universitätsklinikum Hamburg-Eppendorf

Status and phase: Active, not recruiting; Phase 4

Conditions: Oropharyngeal Cancer

Treatments: Procedure: Resection; Drug: Chemotherapy; Procedure: Salvage neck dissection; Radiation: Radiotherapy

Study type: Interventional

Funder types: Other

Identifiers

NCT03691441

TopROC

Details and patient eligibility

About

Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer

Full description

This trial investigates the effectiveness of transoral head and neck surgery (TOS) for locally advanced, but transorally resectable oropharyngeal cancer followed by risk-adapted adjuvant therapy versus primary radiochemotherapy (definitive chemoradiotherapy, CRTX). Both treatments are internationally accepted standards. The choice of the treatment strategy depends on the preference of the responsible attending physician and on the country of residence. Internationally, mostly definitive chemoradiotherapy is regarded as the standard of care for oropharyngeal cancer. In Germany, however, transoral surgical resection is also well established and commonly practiced. The key question therefore is whether one of the two therapies is more effective than the other in clinical daily routine under the given conditions of our health care system and with a realistic, non-ideal patient cohort. For this reason, a comparative effectiveness research (CER) concept will be applied in this setting. The aim of this trial is primarily to show a superiority of the surgical approach in terms of local and locoregional control and secondarily to compare functional outcome and quality of life.

Enrollment: 280 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically proven SCC of the oropharynx; T1, N2a-c, M0; T2, N1-2c, M0; T3, N0-2c, M0, with only amendable to transoral resection)
• Primary tumor must be resectable through transoral approach
• p16 immunohistochemitry by local pathology or FFPE tissue must be available for central HPV diagnostic
• Written and signed informed consent
• Briefing through surgeon and radiation oncologist
• ECOG PS ≥2, Karnofsky PS ≥ 60 %
• Age ≥ 18
• Curative treatment intent
• Adequate bone marrow function: leucocytes > 3.0 x 109/L, neutrophils > 1.5 x 109/L, platelets > 80 x 109/L, hemoglobin > 9.5 g/dL
• Adequate liver function: Bilirubin < 2.0 g/dL, SGOT, SGPT, < 3 x ULN
• If of childbearing potential, willingness to use effective contraceptive method for the study duration and 2 months post-dosing.
• dental examination and appropriate dental therapy if needed prior to Confidential TopROC 2017_03_24 Version 1.0 Seite 15 von 124 beginning of radiotherapy
• Nutritional evaluation prior to initiation of therapy and optional prophylactic gastrostomy (PEG) tube placement

Exclusion criteria

• Prior invasive malignancy except controlled skin cancer or carcinoma in situ of cervix
• Unknown primary (CUP), nasopharynx, hypopharynx, laryngeal or salivary gland cancer
• Metastatic disease
• Serious co-morbidity, e.g. high-grade carotid artery stenosis, congestive heart failure NYHA grade 3 and 4, liver cirrhosis CHILD C
• Hemoglobin level <9.5g/dl within 4 weeks before randomization
• Pregnancy or lactation
• Women of child-bearing potential with unclear contraception
• Previous treatment with chemotherapy, radiotherapy, EGFR-targeting agents or surgery exceeding biopsy in head and neck
• Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study screening
• Social situations that limit compliance with study requirements or patients with an unstable condition (e.g., psychiatric disorder, a recent history of drug or alcohol abuse, interfering with study compliance, within 6 months prior to screening) or otherwise thought to be unreliable or incapable of complying with the requirements of the protocol
• Patients institutionalized by official means or court order
• Deficient

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

280 participants in 2 patient groups

Resection/adjuvant radio(-chemo)therapy

Experimental group

Description:

* Transoral surgical resection within 4 weeks after randomization * Neck dissection can be performed during resection of the primary tumor or within 4 weeks after randomization * 6-7 weeks standard risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy according to arm B if necessary), start within 6 weeks post-surgery

Treatment:

Drug: Chemotherapy

Radiation: Radiotherapy

Procedure: Resection

Adjuvant radio(-chemo)therapy/salvage neck dissection

Active Comparator group

Description:

* 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization * 70-72 Gy, SIB possible * Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (30-40 mg/m2) on days 1, 8, 15, 22, 29, 36 or Mitomycin C 10 mg/m2 d1, 29 and 5-FU 600 mg/m2/day iv on days 1-5 or Cisplatin 20 mg/m² + 5-FU 600 mg/m²/day iv d 1-5 and 29-33 * +/- Salvage neck dissection 12±2 weeks after treatment

Treatment:

Drug: Chemotherapy

Procedure: Salvage neck dissection

Radiation: Radiotherapy